HEPCVIR L 400MG SOFOSBUVIR LEDIPASVIR TABLETS

Get a Price/Quote

HEPCVIR L 400MG SOFOSBUVIR LEDIPASVIR TABLETS Specification

Origin of Medicine
India

Pacakaging (Quantity Per Box)
28 tablets

Indication
Chronic Hepatitis C Virus (HCV) infection

Salt Composition
Sofosbuvir 400mg + Ledipasvir 90mg

Dosage Form
Oral Tablets

Drug Type
Allopathic

Ingredients
Sofosbuvir 400mg and Ledipasvir 90mg

Physical Form
Tablets

Function
Antiviral agent

Recommended For
Treatment of chronic hepatitis C infection

Dosage
As directed by physician

Dosage Guidelines
Take one tablet daily, with or without food, as prescribed

Suitable For
Adults

Quantity
28 tablets per box

Storage Instructions
Store below 30C and protect from moisture

Administration Route
Oral

Therapeutic Class
Antiviral medication

Shelf Life
24 months

Brand Name
HEPCVIR L

Shape
Oval

Color
Yellow

Prescription Required
Yes

Warnings
Not recommended for use in patients with severe renal impairment without specialist advice

Patient Counseling Information
Inform physician of all medications being taken and any history of liver problems or allergies

HEPCVIR L 400MG SOFOSBUVIR LEDIPASVIR TABLETS Trade Information

Packaging Details
PACK OF 28 TABLETS

Main Domestic Market
All India

About HEPCVIR L 400MG SOFOSBUVIR LEDIPASVIR TABLETS

Hepcvir L Cipla

Hepcvir L Sofosbuvir & Ledipasvir

Specifications:

Brand Name : Hepcvir L
Content: Sofosbuvir and Ledipasvir
Strength: Sofosbuvir 400 mg & Ledipasvir 90 mg
Packing: 1X28 Tablets
Type: Tablets
Uses: Hepatitis C
Manufactured By : Cipla

Note : Hepcvir L Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.............

Comprehensive Antiviral Therapy

HEPCVIR L provides targeted treatment for chronic hepatitis C infection, combining two potent antiviral agentsSofosbuvir and Ledipasvir. This dual mechanism helps suppress viral activity, potentially leading to improved liver function and reducing the risk of disease progression. The therapy is suitable for adults under direct medical supervision.

Easy-To-Use Oral Administration

The medication is administered orally as a single tablet daily, with or without food. Its convenient dosage form enhances patient compliance, allowing integration into daily routines while maintaining therapeutic effectiveness. The tablets are distinctively yellow and oval, packaged securely to ensure protection from moisture.

Patient Safety and Counseling

Before starting HEPCVIR L, it is essential for patients to inform their physician about any existing medications, allergies, or liver-related health concerns. Special precaution is advised for those with severe renal impairment. Continuous communication with your healthcare provider supports individualized treatment and minimizes risks.

FAQs of HEPCVIR L 400MG SOFOSBUVIR LEDIPASVIR TABLETS:

Q: How should HEPCVIR L tablets be taken?

A: HEPCVIR L tablets should be taken orally once daily, as prescribed by your physician. They may be taken with or without food, and adherence to the dosage schedule is essential for optimal results.

Q: What is the primary benefit of using HEPCVIR L?

A: HEPCVIR L is designed to effectively treat chronic hepatitis C infection in adults, working to reduce the viral load in the body and support improved liver health.

Q: When should I inform my doctor before starting HEPCVIR L?

A: You should inform your doctor about any other medications you are taking and disclose any history of liver problems or allergies before beginning therapy with HEPCVIR L.

Q: Where should HEPCVIR L be stored to maintain its efficacy?

A: HEPCVIR L should be stored below 30C and away from moisture to preserve its quality and effectiveness throughout its shelf life.

Q: What precautions must be taken during HEPCVIR L treatment?

A: Patients with severe renal impairment should consult a specialist before using HEPCVIR L, and regular medical follow-ups are recommended to monitor safety and therapeutic progress.